ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,764Medicare Part D Prescriptions Filled, Including Refills

Rank: 51 out of 198

$506K Total Retail Price of All Prescriptions

Rank: 56 out of 198

408 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
21% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 408 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

12% of this provider’s 408 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

2% of this provider’s 9,430 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$47 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
LISINOPRIL 460 428 1 6
AMLODIPINE BESYLATE 429 414 2 4
OMEPRAZOLE 382 356 3 3
SIMVASTATIN 377 352 4 2
LEVOTHYROXINE SODIUM 369 318 5 1
FUROSEMIDE 342 327 6 5
ATENOLOL 320 307 7 17
WARFARIN SODIUM 291 225 8 7
ATORVASTATIN CALCIUM 279 269 9 12
POTASSIUM CHLORIDE 275 263 10 9
TAMSULOSIN HCL 157 149 11 27
LOSARTAN POTASSIUM 153 138 12 18
HYDROCODONE-ACETAMINOPHEN 140 123 S3 13 8
ALLOPURINOL 139 103 14 23
ALENDRONATE SODIUM 139 139 14 21
METOPROLOL TARTRATE 134 118 16 10
GABAPENTIN 128 120 17 14
DONEPEZIL HCL 126 126 18 28
TRAMADOL HCL 121 120 19 15
GLIPIZIDE ER 110 86 20 83
HYDROCHLOROTHIAZIDE 109 109 21 16
LANTUS 107 74 22 46
TRIAMTERENE-HCTZ 100 98 23 32
CLONIDINE HCL 96 96 24 52
METFORMIN HCL 94 91 25 13
CITALOPRAM HBR 93 91 26 20
CYCLOBENZAPRINE HCL 93 76 R 26 67
METFORMIN HCL ER 86 74 28 64
POLYETHYLENE GLYCOL 3350 83 68 29 41
NAMENDA 81 81 30 33
HUMALOG 77 50 31 128
PREDNISONE 75 66 32 29
CRESTOR 75 75 32 26
ZOLPIDEM TARTRATE 74 55 34 22
VENLAFAXINE HCL ER 73 43 35 84
GLIPIZIDE XL 73 60 35 152
OXYBUTYNIN CHLORIDE 71 71 37 89
BISOPROLOL FUMARATE 67 55 38 87
TRAZODONE HCL 67 60 38 50
INSULIN SYRINGE 63 48 40 95
PAROXETINE HCL 63 58 40 65
CELEBREX 63 41 40 59
DILTIAZEM ER 61 40 43 98
CARVEDILOL 59 52 44 24
SERTRALINE HCL 57 43 45 25
ACETAMINOPHEN-CODEINE 57 46 S3 45 135
DIOVAN 54 53 47 34
ROPINIROLE HCL 53 46 48 74
FLUOXETINE HCL 53 38 48 78
JANTOVEN 51 51 50 286
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 19, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.